NEW YORK (GenomeWeb) – Genotype has a part to play in how much an individual responds to a placebo in a clinical trial, according to a new review published today in Trends in Molecular Medicine. The findings suggest that clinical trial designers could achieve better results by more carefully constructing the placebo arm, but also raise a litany of ethical questions about the disclosure of genetic information.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.